GHRP-6 vs Thymosin Beta-4
Well Studied vs Well Studied
synergistic Mechanism-based · 47% GHRP-6 and Thymosin Beta-4 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
GHRP-6 Thymosin Beta-4
Weight 873 Da 4,963.44 Da
Half-life 15-60 minutes Dose-dependent; relatively short (exact values not established)
Chain 6 amino acids 43 amino acids
Type Synthetic hexapeptide Thymosin peptide
Key Benefits
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
Thymosin Beta-4
01 Systemic regenerative effects
02 Proven clinical efficacy
03 Optimal bioavailability for tissue repair
04 Promotes angiogenesis
05 Reduces inflammation
Dosing Protocols
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
Thymosin Beta-4
2-6mg per injection (varies by protocol and severity) / Daily for acute healing, 2x weekly for maintenance/chronic conditions
Acute Wound Healing 1.6mg Daily
Cardiac Protection 42mg Single dose
Chronic Tissue Repair 6mg Twice weekly
Neurological Recovery 30mg Three times over 72 hours
General Regeneration 2-5mg Daily or every other day
Side Effects
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Thymosin Beta-4
Mild injection site reactions
Local inflammation at injection sites
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Active chemotherapy treatment
Severe systemic allergies to peptides
Research Evidence
GHRP-6 Thymosin Beta-4
Status Well Studied Well Studied
References 3 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.